{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Supernus+Pharmaceuticals%2C+Inc.",
    "query": {
      "sponsor": "Supernus Pharmaceuticals, Inc."
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 69,
    "total_pages": 7,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Supernus+Pharmaceuticals%2C+Inc.&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-01T13:47:25.788Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04099667",
      "title": "Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Spasticity"
      ],
      "interventions": [
        {
          "name": "Phase 2; Low Dose MYOBLOC (15,000 Units)",
          "type": "DRUG"
        },
        {
          "name": "Phase 2; High Dose MYOBLOC (20,000 Units)",
          "type": "DRUG"
        },
        {
          "name": "Phase 2; Placebo",
          "type": "DRUG"
        },
        {
          "name": "Phase 3; MYOBLOC",
          "type": "DRUG"
        },
        {
          "name": "Phase 3; Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 40,
      "start_date": "2019-12-17",
      "completion_date": "2023-03-24",
      "has_results": true,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-09-01T13:47:25.788Z",
      "location_count": 4,
      "location_summary": "Downey, California • Boise, Idaho • Port Royal, South Carolina + 1 more",
      "locations": [
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Boise",
          "state": "Idaho"
        },
        {
          "city": "Port Royal",
          "state": "South Carolina"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04099667"
    },
    {
      "nct_id": "NCT01770145",
      "title": "Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Parkinson's Disease",
        "Motor Symptoms",
        "Akinesia",
        "Hypomobility",
        "Delayed Levodopa Onset"
      ],
      "interventions": [
        {
          "name": "APOKYN",
          "type": "DRUG"
        },
        {
          "name": "L-dopa",
          "type": "DRUG"
        },
        {
          "name": "Trimethobenzamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 127,
      "start_date": "2012-12",
      "completion_date": "2014-04",
      "has_results": true,
      "last_update_posted_date": "2023-08-14",
      "last_synced_at": "2026-09-01T13:47:25.788Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • Reseda, California • Washington D.C., District of Columbia + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Reseda",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01770145"
    },
    {
      "nct_id": "NCT05066672",
      "title": "Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Treatment Resistant Depression"
      ],
      "interventions": [
        {
          "name": "NV-5138",
          "type": "DRUG"
        },
        {
          "name": "matched placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Navitor Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 250,
      "start_date": "2022-01-18",
      "completion_date": "2025-01-21",
      "has_results": true,
      "last_update_posted_date": "2026-04-17",
      "last_synced_at": "2026-09-01T13:47:25.788Z",
      "location_count": 1,
      "location_summary": "Bellevue, Washington",
      "locations": [
        {
          "city": "Bellevue",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05066672"
    },
    {
      "nct_id": "NCT00515437",
      "title": "A Multi-Center Study of MYOBLOC for the Treatment of Sialorrhea in Parkinson's Disease Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Drooling"
      ],
      "interventions": [
        {
          "name": "Botulinum Toxin Type B (Myobloc)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Matched placebo to Myobloc",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 54,
      "start_date": "2007-07",
      "completion_date": "2008-09",
      "has_results": true,
      "last_update_posted_date": "2026-04-21",
      "last_synced_at": "2026-09-01T13:47:25.788Z",
      "location_count": 18,
      "location_summary": "Scottsdale, Arizona • Northridge, California • Oxnard, California + 15 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "Oxnard",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00515437"
    },
    {
      "nct_id": "NCT00908349",
      "title": "Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Partial Epilepsy"
      ],
      "interventions": [
        {
          "name": "Oxcarbazepine XR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Supernus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "66 Years",
        "sex": "ALL",
        "summary": "18 Years to 66 Years"
      },
      "enrollment_count": 214,
      "start_date": "2009-06",
      "completion_date": "2011-11",
      "has_results": true,
      "last_update_posted_date": "2017-05-31",
      "last_synced_at": "2026-09-01T13:47:25.788Z",
      "location_count": 20,
      "location_summary": "Huntsville, Alabama • Northport, Alabama • Phoenix, Arizona + 17 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Northport",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00908349"
    },
    {
      "nct_id": "NCT05059600",
      "title": "A Study To Assess The Safe-Use Conditions For Administration of ZULRESSO® in a Home Setting",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Postpartum Depression"
      ],
      "interventions": [
        {
          "name": "ZULRESSO®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Supernus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 52,
      "start_date": "2021-10-08",
      "completion_date": "2022-07-14",
      "has_results": true,
      "last_update_posted_date": "2025-09-15",
      "last_synced_at": "2026-09-01T13:47:25.788Z",
      "location_count": 6,
      "location_summary": "Culver City, California • Miramar, Florida • Pompano Beach, Florida + 2 more",
      "locations": [
        {
          "city": "Culver City",
          "state": "California"
        },
        {
          "city": "Culver City",
          "state": "California"
        },
        {
          "city": "Miramar",
          "state": "Florida"
        },
        {
          "city": "Pompano Beach",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05059600"
    },
    {
      "nct_id": "NCT05655520",
      "title": "A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Huntington's Disease"
      ],
      "interventions": [
        {
          "name": "SAGE-718",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Supernus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "25 Years to 65 Years"
      },
      "enrollment_count": 153,
      "start_date": "2022-12-14",
      "completion_date": "2025-01-20",
      "has_results": true,
      "last_update_posted_date": "2025-12-17",
      "last_synced_at": "2026-09-01T13:47:25.788Z",
      "location_count": 29,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 25 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05655520"
    },
    {
      "nct_id": "NCT05049343",
      "title": "Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "SAGE-904",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Ketamine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Supernus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "21 Years to 55 Years"
      },
      "enrollment_count": 22,
      "start_date": "2021-09-21",
      "completion_date": "2021-12-03",
      "has_results": false,
      "last_update_posted_date": "2025-09-17",
      "last_synced_at": "2026-09-01T13:47:25.788Z",
      "location_count": 1,
      "location_summary": "Newark, New Jersey",
      "locations": [
        {
          "city": "Newark",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05049343"
    },
    {
      "nct_id": "NCT00772603",
      "title": "Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Epilepsies, Partial"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "2400mg SPN-804",
          "type": "DRUG"
        },
        {
          "name": "1200mg SPN-804",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Supernus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 366,
      "start_date": "2008-11",
      "completion_date": "2010-11",
      "has_results": true,
      "last_update_posted_date": "2014-02-11",
      "last_synced_at": "2026-09-01T13:47:25.788Z",
      "location_count": 23,
      "location_summary": "Huntsville, Alabama • Northport, Alabama • Phoenix, Arizona + 20 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Northport",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00772603"
    },
    {
      "nct_id": "NCT02618434",
      "title": "Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Attention Deficit Hyperactivity Disorder (ADHD)"
      ],
      "interventions": [
        {
          "name": "SPN-810 (18 mg)",
          "type": "DRUG"
        },
        {
          "name": "SPN-810 (36 mg)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Supernus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "6 Years to 12 Years"
      },
      "enrollment_count": 297,
      "start_date": "2016-02-16",
      "completion_date": "2020-02-14",
      "has_results": true,
      "last_update_posted_date": "2024-03-18",
      "last_synced_at": "2026-09-01T13:47:25.788Z",
      "location_count": 32,
      "location_summary": "Chandler, Arizona • Little Rock, Arkansas • Imperial, California + 29 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Imperial",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Panorama City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02618434"
    }
  ]
}